Clinical trial · Observational
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
NCT04553458CI-TRIAL-00047197completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combined radiofrequency ablation + percutaneous ethanol injection | Combination Product | — | UNRESOLVED |
| Liver resection | Procedure | — | UNRESOLVED |
| Percutaneous ethanol injection | Drug | — | UNRESOLVED |
| Radiofrequency ablation | Device | — | UNRESOLVED |
| Sorafenib | Drug | Sorafenib | ALIAS |
| Symptomatic treatment | Drug | — | UNRESOLVED |
| Systemic chemotherapy | Drug | — | UNRESOLVED |
| Trance-arterial chemoembolization | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Favorable outcome
- description
- Cure or stable disease
- interventionNames
- Device: Radiofrequency ablation
- Drug: Trance-arterial chemoembolization
- Procedure: Liver resection
- Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection
- Drug: Percutaneous ethanol injection
- label
- Unfavorable outcome
- description
- Progressive (deteriorate/Recurrence) or Death
- interventionNames
- Device: Radiofrequency ablation
- Drug: Trance-arterial chemoembolization
- Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection
- Drug: Percutaneous ethanol injection
- Drug: Systemic chemotherapy
- Drug: Sorafenib
- Dietary Supplement: Viscum
- Drug: Symptomatic treatment
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients * with hepatocellular carcinoma Exclusion Criteria: * severely-ill patients * With other system comorbidities, * presence of extrahepatic metastasis, * patients who dropped from the follow-up list after treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.